Join to View Full Profile
220 Fifth Avenue11th FloorNew York, NY 10001
Dr. O'Donnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am an Assistant Professor of Psychiatry at the NYU School of Medicine, and a board-certified psychiatrist practicing in New York City. At the NYU Psychedelic Medicine Research Program, my current focus is on clinical trials of psychedelic substances for the treatment of addiction, trauma, and mood disorders. I am particularly interested in the psychotherapy framework for psychedelic medicine, and in training the next generation of psychedelic therapists and facilitators.
Education & Training
David Geffen School of Medicine at UCLAClass of 2015
UCLAPhD, Neuroscience, 2009 - 2013
Certifications & Licensure
NY State Medical License 2016 - 2025
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 48 citationsNeurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish EmbryosAaron Lulla, Lisa M. Barnhill, Gal Bitan, Magdalena I. Ivanova, Binh Nguyen
Environmental Health Perspectives. 2016-06-15 - 140 citationsAldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson diseaseArthur G. Fitzmaurice, Shannon L. Rhodes, Aaron Lulla, Niall P. Murphy, Hoa A. Lam
Proceedings of the National Academy of Sciences of the United States of America. 2013-01-08 - 52 citationsDynamics of degeneration and regeneration in developing zebrafish peripheral axons reveals a requirement for extrinsic cell types.Rosario Villegas, Seanna M. Martin, Kelley C. O’Donnell, Simón A. Carrillo, Alvaro Sagasti
Neural Development. 2012-06-08
Press Mentions
Psychedelic Drug Therapy May Help Treat Alcohol AddictionAugust 24th, 2022- Psychedelic Drug MDMA Faces FDA Panel in Bid to Become First-of-a-kind PTSD MedicationJune 5th, 2024
Professional Memberships
- Member
- Anxiety and Depression Association of AmericaMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
